Takeda to Acquire GammaDelta Therapeutics to Accelerate Development of Allogeneic γδT Cell Therapies Addressing Solid Tumors

 OSAKA, Japan, & LONDON -Friday 29 October 2021 [ AETOS Wire ]

− Acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging γδT cells for the potential treatment of solid tumors and hematological malignancies

− As result of successful “build-to-buy” collaboration, Takeda to exercise its right to acquire GammaDelta Therapeutics for a pre-negotiated upfront and future potential milestone payments, subject to certain adjustments

(BUSINESS WIRE)-- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the exercise of its option to acquire GammaDelta Therapeutics Limited (“GammaDelta”), a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy. Through the acquisition, Takeda will obtain GammaDelta’s allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, which includes both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211027005677/en/

“We’re committed to developing cell therapies that will have an impact on large segments of patients by focusing on off-the-shelf, allogeneic cell therapies that are highly accessible and have the potential to address solid tumors. Collaborating with scientific innovators with unique technology platforms and deep domain expertise, such as the GammaDelta team, allows Takeda to identify and accelerate the most promising approaches that can be developed into products to impact the lives of cancer patients,” said Christopher Arendt, Ph.D., Head of Oncology Cell Therapy and Therapeutic Area Unit of Takeda. “Gamma-delta T cell-based therapies represent a differentiated approach to target both solid tumors and hematological malignancies, and we are eager to integrate GammaDelta’s cell therapy platforms into our immuno-oncology R&D efforts.”

Takeda exercised its option to acquire GammaDelta for a pre-negotiated upfront payment as well as potential development and regulatory milestones. The acquisition follows a multi-year collaboration between Takeda and GammaDelta Therapeutics formed in 2017 to develop GammaDelta’s novel γδ T cell therapy platforms, in which Takeda received an equity stake and an exclusive right to purchase GammaDelta. The deal is expected to be finalized in Q1 of Takeda’s fiscal year 2022. Closing of the transaction is contingent on completion of review under antitrust laws, including the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 in the U.S.

“Takeda’s exercise of their acquisition option is the culmination of years of a fruitful collaborative partnership and recognizes GammaDelta Therapeutics’ promising progress in developing novel platform technologies to treat solid tumors and hematological malignancies,” said Dr. Paolo Paoletti, CEO of GammaDelta. “Through our work together, we’ve made great strides in developing our proprietary γδ T cell therapy platforms, which have enabled the development of a pipeline of innovative cell therapies and allowed for the advancement of our first program into Phase 1 clinical development. This acquisition builds on the tremendous work of our talented team and provides the foundations to enable rapid development of a portfolio of innovative allogeneic cell therapies, focused on improving outcomes for patients with cancer.”

Tim Haines, Chair and Managing Partner of Abingworth, the founding investor in GammaDelta, added: “We are delighted to have been involved in the creation of GammaDelta and to have worked closely with the leadership team and alongside an excellent partner in Takeda to progress this world-class UK academic science to the next stage of its development.”

Takeda seeks to broaden the impact of immunotherapy in cancer treatment by focusing on mechanisms that leverage innate immunity. Innate immune responses serve as the body’s first defense mechanism against disease and involve the orchestration of a broad arsenal of mechanisms and cell types, including γδ T cells and natural killer (NK) cells, that may help to overcome cancer’s ability to evade immune recognition. GammaDelta’s cell therapy platforms include technologies designed to generate both blood- and tissue-derived allogeneic immunotherapies based on γδ T cells for the treatment of hematological malignancies and solid tumors. Both platforms have enabled the creation of a portfolio of selective non-engineered and genetically-engineered allogeneic cell therapies that are highly active preclinically against solid tumors and hematological malignancies.

Takeda’s Commitment to Oncology

Our core R&D mission is to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. Whether it’s with our hematology therapies, our robust pipeline, or solid tumor medicines, we aim to stay both innovative and competitive to bring patients the treatments they need. For more information, visit www.takedaoncology.com

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com.

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

About GammaDelta Therapeutics

GammaDelta Therapeutics (“GammaDelta”) is clinically-staged biotechnology company pioneering the discovery and development of allogeneic gamma delta T cell therapies for cancer. Committed to transforming the treatment of patients living with cancer, the Company is developing an ‘off-the-shelf’ therapy based on one of the body’s own immune cells, a subtype of the gamma delta (γδ) T-lymphocyte, known as the Vδ1+ T cell.

The Company has developed proprietary technologies to generate both blood-and tissue-derived allogeneic immunotherapies based on Vδ1 γδ T cells for the treatment of hematological malignancies and solid tumors. Both platforms have enabled the creation of non-engineered and genetically engineered allogeneic cell therapies, which demonstrate cellular activity and tumor cell killing capacity in pre-clinical models.

GammaDelta is advancing its novel, γδ T cell platforms and product candidates under an ongoing collaboration with Takeda Pharmaceutical Company Limited (“Takeda”). GammaDelta’s technologies are based on pioneering world-class research conducted by Professor Adrian Hayday and Dr Oliver Nussbaumer, at King’s College London and the Francis Crick Institute, and Professor Bruno Silva-Santos at the University of Lisbon. Early-stage research was facilitated in part by the support and the infrastructure of the National Institute for Health Research Guy’s and St Thomas’ Biomedical Research Centre. The formation of GammaDelta as a company was supported by Cancer Research UK Commercial Partnerships. GammaDelta’s technologies have attracted significant investment from Takeda and leading life sciences investor, Abingworth LLP.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005677/en/

Contacts
Takeda Media:
Japanese Media
Ritsuko Nomura
ritsuko.nomura@takeda.com
+81 (0) 466-32-4520

Media outside Japan
Chris Stamm
chris.stamm@takeda.com
+1 (617) 347-7726

GammaDelta:
Sarah Jeffery
Zyme Communications
sarah.jeffery@zymecommunications.com
+44 (0) 7771 730 919

 


Permalink : https://www.aetoswire.com/news/takeda-to-acquire-gammadelta-therapeutics-to-accelerate-development-of-allogeneicnbspgammadeltat-cell-therapies-addressing-solid-tumors/en

Boehringer Ingelheim announces European Medicines Agency’s filing acceptance and validation of marketing authorization application for spesolimab in generalized pustular psoriasis

INGELHEIM, Germany -Friday 29 October 2021 [ AETOS Wire ]

The marketing authorization application (MAA) package includes results from the pivotal Effisayil-1 global trial

(BUSINESS WIRE)-- Boehringer Ingelheim announced today that the company’s marketing authorization application (MAA) for the treatment of flares in generalized pustular psoriasis (GPP), has been validated and is now under evaluation with the European Medicines Agency (EMA).

“GPP is a rare, life-threatening neutrophilic skin disease characterized by painful, sterile pus-filled blisters, that can suddenly appear over the body,” said Dr. Janine Lamar, Global Spesolimab Lead at Boehringer Ingelheim. “Despite its name, GPP is very different to the more common plaque psoriasis. With no approved treatments in the EU for GPP flares, acceptance of the application for review of spesolimab brings us one step closer to providing a targeted treatment for people with this distressing, unpredictable and painful skin condition.”

GPP is characterized by episodes of widespread eruptions of painful, sterile pustules (blisters of non-infectious pus).1,2,3 The inflammation can also affect other parts of the body and can lead to infections or other organ complications that may be life-threatening.

There is a high unmet need for treatments that can rapidly and completely resolve the symptoms of GPP flares. Flares greatly affect a person’s quality of life4 and can lead to hospitalization with life-threatening complications, such as heart failure, renal failure, sepsis and even death.5

The marketing authorization application was based on the 12 week Effisayil-1 trial; a multi-center, double-blind, randomized, placebo-controlled trial that evaluated efficacy, safety, and tolerability of spesolimab (single dose 900 mg spesolimab i.v., with the option of a 2nd dose if symptoms persisted on Day 8) in patients experiencing a GPP flare.6 The study demonstrated superiority over placebo in pustular clearance after one week of treatment.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/ema-filing-acceptance-and-validation-spesolimab

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005027/en/

Contacts

Boehringer Ingelheim

Corporate Communications

Media + PR

Dr Julia Faass

Phone: +49 (6132) 77 95614

Fax: +49 (6132) 77 6601

Email: press@boehringer-ingelheim.com

Additional information

www.boehringer-ingelheim.com

SDCL EDGE Acquisition Corporation Announces Pricing of $175 Million Initial Public Offering

 NEW YORK-Friday 29 October 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- SDCL EDGE Acquisition Corporation (the “Company”) announced today that it priced its initial public offering of 17,500,000 units at $10.00 per unit. The units will be listed on The New York Stock Exchange (“NYSE”) and trade under the ticker symbol “SEDA.U” beginning October 29, 2021. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. Once the securities comprising the units begin separate trading, the Class A ordinary shares and redeemable warrants are expected to be listed on the NYSE under the symbols “SEDA” and “SEDA WS”, respectively. The offering is expected to close on November 2, 2021, subject to customary closing conditions.

Goldman Sachs & Co. LLC and BofA Securities, Inc. are acting as joint book-running managers for this offering. The Company has granted the underwriters a 45-day option to purchase up to an additional 2,625,000 units at the initial public offering price to cover over-allotments, if any.

The offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering and the final prospectus, when available, may be obtained from Goldman Sachs & Co. LLC, 200 West Street, New York, NY 10282, Attn: Prospectus Department, by telephone at 866-471-2526, facsimile at 212-902-9316 or by emailing prospectus-ny@ny.email.gs.com or BofA Securities, Inc., NC1-004-03-43, Attn: Prospectus Department, at 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001 or by email at dg.prospectus_requests@bofa.com.

A registration statement relating to the securities was declared effective by the Securities and Exchange Commission (the “SEC”) on October 28, 2021. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About SDCL EDGE Acquisition Corporation

SDCL EDGE Acquisition Corporation is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus on opportunities created by the rapid shift towards energy efficient and decentralized energy solutions for a lower carbon economy and, in particular, for the built environment and transport sectors.

Forward-Looking Statements

This press release contains statements that constitute “forward-looking statements,” including with respect to the proposed initial public offering. No assurance can be given that the offering will be completed on the terms described, or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the “Risk Factors” section of the Company’s registration statement for the Company’s offering filed with the U.S. SEC and the preliminary prospectus included therein. Copies of these documents are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contacts

Ned Davis

Chief Financial Officer, SDCL EDGE Acquisition Corporation

Telephone: 212-488-5509

Email: investors@sdcledge.com

Kelly McAndrew

Financial Profiles, Inc.

Telephone: 203-613-1552

Email: kmcandrew@finprofiles.com

Moira Conlon

Financial Profiles, Inc.

Telephone: 310-622-8220

Email: mconlon@finprofiles.com

Permalink : https://www.aetoswire.com/news/sdcl-edge-acquisition-corporation-announces-pricing-of-175-million-initial-public-offering/en

The Gillette Gaming Alliance Returns for its Fourth Consecutive Year

 Team of top global gaming streamers unite to represent the brand and engage with fans worldwide

BOSTON -Friday 29 October 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Gillette (NYSE: PG), the world’s leading expert in men’s grooming, announced today the return of the Gillette Gaming Alliance -- a team of global streamers selected to represent the brand and create content for audiences worldwide. The Gillette Gaming Alliance, which is back for its fourth consecutive year, features the largest roster to date – with streamers representing a total of 11 countries – making it a truly worldwide edition.

Each member of the Alliance will create custom content streams as well as highlight their shaving routines, personal style and Gillette’s newest innovation, core products including ProGlide and SkinGuard, initiatives such as Movember, and promotions when applicable. Members will come together for co-stream opportunities, also known as squad streams, as well as stream individually throughout the duration of the year. And, for the first team in Gillette Gaming Alliance history, streamers will be sharing content on multiple platforms including Twitch, YouTube and TikTok, too.

“We are excited to evolve our Gillette Gaming Alliance for the fourth consecutive year – expanding our streamer roster, adding more countries, and incorporating new social platforms to make it bigger and better,” explains Gary Coombe, CEO, Gillette.

Gillette Gaming Alliance veterans – including Alanzoka (Brazil), Elded (Mexico), DrLupo (North America), DeejayKnight (North America), Buster (Russia) and LandoNorris (United Kingdom) – make their return, alongside new additions including oCastrin (Brazil), Jolavanille (France), Juansguarnizo (Mexico), DreadzTV (Russia), and Silvername (Russia), among others. The Gillette Gaming Alliance will welcome additional members to the squad throughout the year to continue driving buzz and excitement worldwide.

Additionally, on behalf of Gillette, Alliance members will be highlighting consumer and fan giveaways on-stream throughout the program to further engage the global community.

“It is an honor to be a part of the Gillette Gaming Alliance as we continue to bring new content and exciting opportunities to our fans worldwide,” adds DrLupo, one of the most recognizable streamers in the world. “I have always been a big fan of Gillette and use their products daily. It’s really exciting to be able to continue our partnership as this program evolves and raise awareness for a few really awesome initiatives – be sure to follow along to learn more!”

Gillette was recently recognized as “Brand of the Year” at the Tempest Awards for its work in the esports and gaming community.

For more information on the brand, please visit Gillette’s official website here, and on Twitter, Facebook and Instagram.

About Gillette

For more than 120 years, Gillette has delivered precision technology and unrivalled product performance – improving the lives of over 800 million consumers around the world. From shaving and body grooming, to skin care and sweat protection, Gillette offers a wide variety of products including razors, shave gel (gels, foams and creams), skin care, after shaves, antiperspirants, deodorants and body wash. For more information and the latest news on Gillette, visit www.gillette.com. To see our full selection of products, visit www.gillette.com. Follow Gillette on Twitter, Facebook and Instagram.

About Procter & Gamble

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands. For other P&G news, visit us at www.pg.com/news.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005386/en/

Contacts

Kristyn Brown

kristyn.brown@ketchum.com

Permalink : https://www.aetoswire.com/news/the-gillette-gaming-alliance-returns-for-its-fourth-consecutive-year/en

Mitsubishi Corporation Life Sciences to Accelerate Next Wave of Digital Transformation and Business Growth by Switching to Rimini Street Support

  Leading food ingredients manufacturer advances strategic business initiatives and overseas expansion by optimizing support for its JD Edwards Software



LAS VEGAS-Friday 29 October 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Mitsubishi Corporation Life Sciences, a food ingredients manufacturer within Mitsubishi Corporation’s Food Industry Group, has switched to Rimini Street Support for its JD Edwards applications. Switching from the vendor’s support to Rimini Street has enabled the company to dramatically reduce its maintenance costs and free up internal resources for strategic initiatives. By freeing up critical resources – time, money and personnel – Mitsubishi Corporation Life Sciences is able to begin investing in its digital transformation initiatives for the next five to 10 years and establish a foothold for further business expansion, both locally and overseas.

Optimizing Resources to Fuel Digital Transformation

Mitsubishi Corporation Life Sciences Limited is a member of the Mitsubishi Corporation Food Industry Group, which has diversified businesses in a number of market segments. It was formed in April 2019 through the merger of three companies – Mitsubishi Shoji Foodtech, MC Food Specialties and KOHJIN Life Sciences – to launch Mitsubishi Corporation Life Sciences Limited. The company is focused on a five to 10-year plan to transform its business through strategic digital initiatives, including projects to support remote working and flexible working environments, digitizing documents and moving to a paperless environment and utilizing artificial intelligence and big data technologies to support its future business needs.

As part of this reform, the company needed to find budget to begin planning and implementing these new digital initiatives. To support this company-wide initiative, IT reviewed and evaluated its JD Edward system – used for production management including work orders, material requirements planning and order management – to assess the current ROI it was receiving in exchange for the high support costs. The company wanted to continue using its current stable software version for as long as possible and did not see value in future upgrades. In addition, the company felt that the vendor was not providing adequate support for its system – they encountered frequent problems that caused critical issues in their operations but were not receiving quality support to address these issues. For Mitsubishi Corporation Life Sciences, even the slightest downtime seriously impacts its business activities such as accounting, production, sales, purchasing and inventory management. Mitsubishi Corporation Life Sciences sought an alternative approach to address these issues, which led them to Rimini Street.

“We use JD Edwards for many critical business areas such as accounting, production, sales, purchasing and inventory management, and even a momentary downtime would have a serious impact on our business activities. In the past, the vendor’s support for critical software issues that could stop our business has been unsatisfactory. As we looked for ways to both get the quality support we needed and the ability to optimize our investment in the platform, we found out about third-party maintenance support from Rimini Street,” said Shinya Hattori, chief information officer and general manager of Information Systems at Mitsubishi Corporation Life Sciences. “We made the decision to switch to Rimini Street within about six months of starting our evaluation. With the resources we have freed up as a result of this switch, we aim to invest in areas of corporate growth including overseas expansion and will work closely with Rimini Street to build our own IT roadmap for the future.”

Rapid Response and World-Class Support

As with all Rimini Street clients, Mitsubishi Corporation Life Sciences benefits from a flexible, premium-level enterprise software support model that includes industry-leading Service Level Agreements (SLAs) with guaranteed response times of 10 minutes or less for all critical (P1) issues. All clients are also assigned a Primary Support Engineer with an average of 20 years’ experience in the client’s specific enterprise software and backed by a team of functional and technical engineers.

“In the past, the software vendor often failed to quickly respond to our requests for support,” said Yohei Yoshizaki, group manager for the Information Systems Department at Mitsubishi Corporation Life Sciences. “With Rimini Street, we receive a higher quality service, more sincere responses to our inquiries and faster response times.”

“Mitsubishi Corporation Life Sciences is another example of how companies in Japan are optimizing their costs and maximizing their ERP investments to pave the way for digital transformation that help their businesses grow and thrive,” said Yorio Wakisaka, group vice president and regional general manager, Japan, Rimini Street. “By partnering with Rimini Street, they have dramatically reduced their support and maintenance costs enabling them to free up resources that can be redirected to more strategic business imperatives. We look forward to continuing to support Mitsubishi Corporation Life Sciences as they take back the control of their IT roadmap to better drive competitive advantage and growth.”

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® Company, is a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner. The Company offers premium, ultra-responsive and integrated application management and support services that enable enterprise software licensees to save significant costs, free up resources for innovation and achieve better business outcomes. To date, more than 4,200 Fortune 500, Fortune Global 100, midmarket, public sector and other organizations from a broad range of industries have relied on Rimini Street as their trusted application enterprise software products and services provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn.

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our expectations of future events, future opportunities, global expansion and other growth initiatives and our investments in such initiatives. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, the impact of our credit facility’s ongoing debt service obligations and financial covenants and operational covenants on our business and related interest rate risk, the duration of and operational and financial impacts on our business of the COVID-19 pandemic and related economic impact, as well as the actions taken by governmental authorities, clients or others in response to the COVID-19 pandemic; catastrophic events that disrupt our business or that of our current and prospective clients, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse developments in pending litigation or in the government inquiry or any new litigation; our need and ability to raise additional equity or debt financing on favorable terms and our ability to generate cash flows from operations to help fund increased investment in our growth initiatives; the sufficiency of our cash and cash equivalents to meet our liquidity requirements; including under our new credit facility; our ability to maintain an effective system of internal control over financial reporting, and our ability to remediate identified material weaknesses in our internal controls, including in relation to the accounting treatment of our warrants; changes in taxes, laws and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the customer adoption of our recently introduced products and services, including our Application Management Services (AMS), Rimini Street Advanced Database Security, and services for Salesforce Sales Cloud and Service Cloud products, in addition to other products and services we expect to introduce in the near future; the loss of one or more members of Rimini Street’s management team; uncertainty as to the long-term value of Rimini Street’s equity securities; and those discussed under the heading “Risk Factors” in Rimini Street’s Quarterly Report on Form 10-Q filed on August 4, 2021, and as updated from time to time by Rimini Street’s future Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and other filings by Rimini Street with the Securities and Exchange Commission. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Rimini Street’s assessments as of any date subsequent to the date of this communication.

© 2021 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005034/en/

Contacts

Michelle McGlocklin
Rimini Street, Inc.
+1 925 523-8414
mmcglocklin@riministreet.com


Permalink : https://www.aetoswire.com/news/mitsubishi-corporation-life-sciences-to-accelerate-next-wave-of-digital-transformation-and-business-growth-by-switching-to-rimini-street-support/en

Lenovo Launches the Kind City: Interactive Global Collaboration Encourages Empathy and Creates a Future Built on Kindness

 The initiative features world-renowned thought leaders, including British-American fashion designer and philanthropist Tan France, 2020 TIME Kid of the Year Gitanjali Rao, and UK robotics scientist Dr. Peter Scott-Morgan

RESEARCH PARK TRIANGLE, N.C.-Friday 29 October 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- Today, Lenovo™ (HKSE: 992) (ADR: LNVGY) launches the Kind City project—a vision to change urban environments forever and create future cities built on kindness.

By championing empathy in society, the project strives to encourage stronger, more inclusive communities made possible through smarter technology, and restore kindness in places where citizens feel increasingly disconnected.

Lenovo’s Kind City is the biggest crowdsourced public ‘census’ to imagine and co-author a blueprint for a city of the future built on kindness. It’s mission? To bring a more empathetic future to life through insight from global research, a public invitation to participate, and an interactive podcast featuring city dwellers and some of the world’s brightest minds.

“We believe the Kind City project will be the blueprint for mapping a kinder and better future,” said John Gordon, President of Industry Solutions at Lenovo. “Technology can and will make the future kinder, more inclusive, and more equitable. In cities, this means providing smarter technology for all—across socio-economic or cultural backgrounds—including both devices and solutions.”

Kind Council Formation and Interactive Podcast

Bringing together leading thinkers and global experts in their fields, Lenovo’s Kind City is steered by a panel of world-renowned visionaries who make up the project’s “Kind Council.” This includes British-American fashion designer and philanthropist Tan France, 2020 TIME Kid of the Year and inventor Gitanjali Rao, Brazilian rapper Emicida, UK robotics scientist Dr. Peter Scott-Morgan, German futurologist Oona Strathern, and Japanese author and entrepreneur Ibun Hirahara.

The group has collaborated on a choose-your-own-path podcast to discuss the fundamentals in achieving a Kind City, such as inclusion, trust, sustainability, dreams, and opportunity.

As the backbone of the entire initiative, the innovative podcast also explores powerful conversations and incredible stories with voices less commonly heard in futurism. Listeners can navigate from multigenerational living in the USA, to climate change in China, to tech hubs in Brazilian favelas, to dream research in the UK and a kindness currency in Japan.

The insightful and interactive podcast encourages listeners to become part of the discussion while giving them the opportunity to navigate an audio journey personalised to their interests. More than 20 stories, discussions, and interviews were captured from across the globe, from the United States and Germany to Japan and Brazil.

The podcast features NGO and charity partners from around the world, showcasing their efforts to support city residents. Lenovo will work directly with these organizations over the coming months and identify the most impactful ways to collaborate, from workshops on technology solutions with Lenovo experts, to device donations and financial support.

Major New Research Uncovers the ‘Kindness Gap’

The Kind City project comes on the heels of fresh research conducted by Lenovo that dives deep into the lives of city dwellers and their perspectives on the quality of life in their current cities.

Surveying more than 5,000 city dwellers across five countries (Brazil, Germany, Japan, United Kingdom, United States), the study exposes the growing need for society to rethink how we live together in city centers post-pandemic.

Research revealed traditional organizations and government are falling short on prioritizing kindness, leaving it to local neighborhoods and communities to shoulder more than their share of the responsibility.

Ultimately a major ‘Kindness Gap’ exists globally in cities with 97% of all polled believing it is important their communities have kindness/empathy, but only 37% feeling their current city is a kind place to live or work.

While the study finds respondents have a somewhat positive impression of the quality of life where they live, they also draw a clear connection between greater kindness in their cities and many tangible benefits, for example, improved mental and physical health; feelings of inclusivity and pride; greater enjoyment and flexibility, that could unlock even happier lifestyles. A significant opportunity for improvement in the face of these challenges exists, including:

Most respondents (55%) believe the quality of life in their city is either not getting better or staying the same. In cities across the globe, majorities say that there is room for improvement in their general living and working conditions.

 

City residents have reservations about how much the officials that represent them consider kindness when making decisions for the city. Less than one in five (17%) believe their policymakers strongly consider kindness and empathy when it comes to their city.

 

Most residents think technology will be a pivotal solution (83%) for promoting and employing kindness in their cities, most notably in Brazil (88%).

What the kindness gap presents is a real opening to the private sector to enable and empower greater kindness and empathy. More than ever, there’s an urgency to work toward a more equitable future—and we can use the power of technology to make this come to fruition.

Get Involved: Become a Kind City Citizen

The initiative is calling upon people from all walks of life, across every major city to voice their vision of what a kinder city should be.

Lenovo invites the general public to share their personal vision of an empathetic and inclusive community by becoming Kind City citizens, which they can do by simply completing the following statement: “The future of the Kind City will…” on Lenovo’s microsite housing the project KindCity.com.

All responses received through November 15 will be curated using AI and transformed into 10 founding principles. These will be shared across the world through a range of exciting installations and experiential initiatives. Lenovo will also reveal details of collaborations with the global NGOs featured in the podcast, with actions shaped by Kind City submissions and research.

About Lenovo

Lenovo (HKSE: 992) (ADR: LNVGY) is a US$60 billion revenue Fortune Global 500 company serving customers in 180 markets around the world. Focused on a bold vision to deliver smarter technology for all, we are developing world-changing technologies that power (through devices and infrastructure) and empower (through solutions, services and software) millions of customers every day and together create a more inclusive, trustworthy and sustainable digital society for everyone, everywhere. To find out more visit https://www.lenovo.com and read about the latest news via our StoryHub.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211026005167/en/

 

Contacts

Justin Eure, jeure@lenovo.com

Permalink : https://www.aetoswire.com/news/lenovo-launches-the-kind-city-interactive-global-collaboration-encourages-empathy-and-creates-a-future-built-on-kindness/en

Women’s Entrepreneurship Accelerator Announces Partnership With Commonwealth to Drive Change for Women Entrepreneurs in 54 Countries

 NEW YORK -Friday 29 October 2021 [ AETOS Wire ]

(BUSINESS WIRE)-- The Women’s Entrepreneurship Accelerator (WEA), a strategic multi-partnership convening five UN agencies and Mary Kay Inc., is today joining forces with the Commonwealth Businesswomen’s Network (CBWN) to empower and support underserved women entrepreneurs across the 54 countries of the Commonwealth.

WEA is designed to maximize the development impact of women entrepreneurship in achieving the Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs that fosters growth, sustainability, and resilience. In June 2021, WEA joined the Generation Equality Forum in Paris and committed to empower five million women around the world by 2030 to accelerate progress for gender equality.

WEA recently announced the launch of a series of impactful initiatives and knowledge products, all shaped through a gender lens, as the joint outcome of the collaboration between the International Labour Organization (ILO), the International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP) and UN Women with the strategic support and funding of Mary Kay. WEA’s impact work includes digital capacity building tools and training; entrepreneurship research; and gender-responsive procurement (GRP) advocacy and training.

CBWN works with women in business by connecting governments and the private sector to encourage, enable and embed women’s economic empowerment and women in leadership. Originating in May 2021, the Commonwealth Women’s Entrepreneurship Accelerator (CWEA) is a strategic multi-stakeholder partnership from the CBWN, the Global Entrepreneurship Network UK (GEN UK) and Oxentia. It is a direct response to three developments: the agreement by all Commonwealth Heads of Government in London in 2018 “to work towards an increase in the number and enhancement of the success rate of women-owned businesses, break down gender barriers in all sectors, and increase opportunities for women to trade internationally”; the recognition by the G20 in 2020 that “there is a missed opportunity – to tackle the gap that needs immediate action, which is the representation of women in emerging fields”; and the UN Global Acceleration Plan to advance gender equality by 2026 and its Action Coalitions on Economic Justice and Rights and Technology and Innovation launched in 2021.

The new partnership with CBWN in support of CWEA further solidifies WEA’s geographic scope of action across the 54 Commonwealth diverse country members in Africa, Asia, the Americas, Europe, and the Pacific, with 32 countries classified as “small states.” Small states are especially vulnerable to climate change and developmental challenges including gender inequalities.

Beyond scaling WEA and CBWN’s foundational areas of work, the partnership will also significantly focus on policy and advocacy to advance systemic change engaging Commonwealth member states and leveraging its networks of organizations and key stakeholders in support of women in business or aspiring women entrepreneurs in and across the Commonwealth.

“We know that multi-stakeholder partnerships and collective engagement is crucial to drive the change that women entrepreneurs need across sectors around the world,” said Deborah Gibbins, Chief Operating Officer of Mary Kay Inc. “WEA is thrilled to join forces with the Commonwealth Businesswomen’s Network and the Commonwealth Women’s Entrepreneurship Accelerator. Our collaboration will focus on augmenting, amplifying and accelerating impact. We’re more powerful together, and I look forward to our collective action journey in support of the SDGs.”

“The Commonwealth Businesswomen’s Network is delighted to partner with the United Nations Women’s Entrepreneurship Accelerator in this landmark initiative so we can unlock and unleash the power and potential for more women of diverse backgrounds,” said Freda Miriklis, Chair, Commonwealth Businesswomen’s Network. “Through this partnership, we’ll be able to more quickly harness our collective assets - for women, their communities and every girl that can and will be inspired by their stories.”

To learn more about the Women’s Entrepreneurship Accelerator, visit we-accelerate.com.

About the Women’s Entrepreneurship Accelerator

The Women’s Entrepreneurship Accelerator (WEA) is a multi-partnership initiative on women’s entrepreneurship convening 5 UN agencies, International Labour Organization (ILO), International Trade Centre (ITC), UN Global Compact (UNGC), UN Development Programme (UNDP), UN Women and Mary Kay Inc. to empower 5 million women entrepreneurs by 2030.

The ultimate goal of the initiative is to maximize the development impact of women entrepreneurship in achieving Sustainable Development Goals (SDGs) by creating an enabling ecosystem for women entrepreneurs around the world. The Accelerator exemplifies the transformational power of a multi-partnership of unique magnitude to harness the potential of women entrepreneurs.

Learn more at we-accelerate. Follow us: Twitter (@We_Accelerator), Instagram (@we_accelerator), Facebook (@womensentrepreneurshipaccelerator), LinkedIn (@womensentrepreneurshipaccelerator)

About the Commonwealth Businesswomen’s Network

The Commonwealth Businesswomen’s Network (CBWN) works with women in business by connecting Governments and the private sector to encourage, enable and embed women’s economic empowerment. This is achieved through delivering activities, initiatives, products, and services focused on trade, talent, and training. It is the only accredited organisation focused on women’s economic empowerment and directly recognized by 54 governments across six continents. Learn more at www.cbwn.org

About the Commonwealth Women’s Entrepreneurship Accelerator

The Commonwealth Women’s Entrepreneurship Accelerator is a strategic multi stakeholder partnership on women’s entrepreneurship established as an outcome of the inaugural Commonwealth Women’s Entrepreneurship Summit (CWES) in May 2021, the first global event to focus on women in emerging tech sectors. CWES was convened by the Commonwealth Businesswomen’s Network; the Global Entrepreneurship Network; the UK Government (Women in Innovation Network, a programme of Innovation UK); and Africa’s largest network of women entrepreneurs (AWEP: African Women’s Entrepreneurship Program). The Commonwealth Women’s Entrepreneurship Accelerator is a partnership between the Commonwealth Businesswomen’s Network, Global Entrepreneurship Network-UK and Oxentia. Learn more at www.thecwea.org

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company more than 58 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, nutritional supplements, and fragrances. Mary Kay is committed to empowering women and their families by partnering with organizations from around the world, focusing on supporting cancer research, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Mary Kay Ash’s original vision continues to shine—one lipstick at a time. Learn more at marykayglobal.com

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20211027005291/en/

Contacts

Mary Kay Inc. Corporate Communications

marykay.com/newsroom

(+1) 972.687.5332 or   media@mkcorp.com

 Permalink : https://www.aetoswire.com/news/womenrsquos-entrepreneurship-accelerator-announces-partnership-with-commonwealth-to-drive-change-for-women-entrepreneurs-in-54-countries/en